@article{d67842dc6902451096a57ef5b3e97b46,
title = "Bad news and good news in AD, and how to reconcile them",
abstract = "2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.",
author = "Knopman, {David S.}",
note = "Funding Information: This work was supported by NIH grants P50 AG16574, U01 AG06786 and R01 AG41851. Funding Information: D.S.K. serves on a Data Safety Monitoring Board (DSMB) for The Dominantly Inherited Alzheimer Network (DIAN) study for which he receives personal compensation. He serves on a DSMB for Biogen, but all compensation related to that activity goes to his institution. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He does not receive any personal compensation from either Biogen or Lilly as a site investigator; his institution receives funding for those activities. He is an adviser to Samus Pharmaceuticals and Alzeca Biosciences. For both, he receives no personal compensation; his institution receives funding for those activities. He receives research support from the NIH. Avid Radiopharmaceuticals, Inc., supplies Mayo Clinic with AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation that is used in research in which D.S.K. is an investigator. Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",
year = "2019",
month = feb,
day = "1",
doi = "10.1038/s41582-018-0131-7",
language = "English (US)",
volume = "15",
pages = "61--62",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "2",
}